Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neumora Therapeutics (NMRA) Free Cash Flow (2022 - 2026)

Neumora Therapeutics' quarterly Free Cash Flow came in at -$46.4 million in Q1 2026, up 21.94% year-on-year from -$38.1 million in Q1 2025, and up 3.23% quarter-over-quarter from -$48.0 million in Q4 2025.

Neumora Therapeutics has reported Free Cash Flow for 5 years, with the latest figure at -$46.4 million in Q1 2026.

  • For the quarter ending Q1 2026, Free Cash Flow rose 21.94% year-over-year to -$46.4 million; the trailing twelve-month figure through Mar 2026 stood at -$193.4 million (up 3.03% YoY), and the FY2025 full-year result was -$206.4 million, down 12.85% from the prior year.
  • Free Cash Flow for Q1 2026 stood at -$46.4 million, up from -$48.0 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$30.9 million in Q4 2022, with the low at -$59.4 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$45.0 million, with a median of -$47.2 million recorded in 2023.
  • Peak annual rise in Free Cash Flow reached 29.97% in 2024, while the deepest fall reached 81.03% in 2024.
  • Tracing NMRA's Free Cash Flow over 5 years: stood at -$30.9 million in 2022, then plunged by 66.65% to -$51.4 million in 2023, then advanced by 2.09% to -$50.3 million in 2024, then climbed by 4.74% to -$48.0 million in 2025, then rose by 3.23% to -$46.4 million in 2026.
  • The last three Free Cash Flow figures came in at -$46.4 million (Q1 2026), -$48.0 million (Q4 2025), and -$46.6 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Free Cash Flow (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -1.67 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -12.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -2.49 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.29 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 848.30 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 48.67 Mn
10 Neumora Therapeutics 328.27 Mn 328.27 Mn - -46.40 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -46.40 Mn
Mar 31, 2026 -46.40 Mn
Dec 31, 2025 -47.96 Mn
Dec 31, 2025 -47.96 Mn
Sep 30, 2025 -46.63 Mn
Sep 30, 2025 -46.63 Mn
Jun 30, 2025 -52.40 Mn
Jun 30, 2025 -52.40 Mn
Mar 31, 2025 -59.45 Mn
Mar 31, 2025 -59.45 Mn
Dec 31, 2024 -50.34 Mn
Dec 31, 2024 -50.34 Mn
Sep 30, 2024 -33.48 Mn
Sep 30, 2024 -33.48 Mn
Jun 30, 2024 -56.16 Mn
Jun 30, 2024 -56.16 Mn
Mar 31, 2024 -42.96 Mn
Mar 31, 2024 -42.96 Mn
Dec 31, 2023 -51.41 Mn
Dec 31, 2023 -51.41 Mn
Sep 30, 2023 -47.81 Mn
Sep 30, 2023 -47.81 Mn
Jun 30, 2023 -31.02 Mn
Jun 30, 2023 -31.02 Mn
Mar 31, 2023 -33.08 Mn
Mar 31, 2023 -33.08 Mn
Dec 31, 2022 -30.85 Mn
Dec 31, 2022 -30.85 Mn